All lobbying filings

ARENTFOX SCHIFF LLP

ARENTFOX SCHIFF LLP filed a Q2 report for ORGANOGENESIS INC. on July 18, 2026, reporting $80,000 in lobbying income.

Lobbying for ORGANOGENESIS INC. · Biotech company

All filings by ARENTFOX SCHIFF LLP · Everything ORGANOGENESIS INC. has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 18, 2026

Income

$80,000

What the client paid this registrant for the period.

Client based in

Massachusetts

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Medicare/Medicaid

Medicare reimbursement policy for chronic wound healing products, including Local Coverage Determinations and Discarded Products policy Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products (CY2026 and CY2027) Hospital Outpatient Prospective Payment System regulations regarding reimbursement for chronic wound healing products (CY2026 and CY2027) H.R. 5768 and S. 2561 (Skin Substitute Access and Payment Reform Act of 2025), entire bill H.R.6852 (Advanced Wound Care and Regenerative Medicine Access and Reform Act), entire bill

Health Issues

Food and Drug Administration policy on chronic wound healing products

Bills named in this filing 3

H.R. 5768
Skin Substitute Access and Payment Reform Act
S. 2561
Skin Substitute Access and Payment Reform Act of 2025
H.R. 6852
Advanced Wound Care and Regenerative Medicine Access and Reform Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.